The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

doi:10.1038/s41422-021-00496-8

. 2021 Jun;31(6):720-722.

doi: 10.1038/s41422-021-00496-8. Epub 2021 Apr 23.

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

Haolin Liu^#^{1

2}, Qianqian Zhang^#³, Pengcheng Wei^{4

5}, Zhongzhou Chen³, Katja Aviszus^{4

5}, John Yang⁶, Walter Downing⁷, Chengyu Jiang⁸, Bo Liang⁹, Lyndon Reynoso¹⁰, Gregory P Downey⁶, Stephen K Frankel⁶, John Kappler^{4

5}, Philippa Marrack^{11

12}, Gongyi Zhang^{13

14}

Affiliations

¹ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA. Liuh@NJhealth.org.
² Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA. Liuh@NJhealth.org.
³ State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agriculture University, Beijing, 100193, China.
⁴ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA.
⁵ Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA.
⁶ Department of Medicine, National Jewish Health, Denver, CO, 80206, USA.
⁷ Department of Nursing, National Jewish Health, Denver, CO, 80206, USA.
⁸ Chinese Academy of Medical Sciences, Department of Biochemistry and Molecular Biology, Peking Union Medical College, Tsinghua University, Beijing, 100005, China.
⁹ Department of Biochemistry, Emory University of School of Medicine, Atlanta, GA, 30322, USA.
¹⁰ Department of Pharmacy, National Jewish Health, Denver, CO, 80206, USA.
¹¹ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA. Marrackp@NJhealth.org.
¹² Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA. Marrackp@NJhealth.org.
¹³ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA. Zhangg@NJhealth.org.
¹⁴ Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA. Zhangg@NJhealth.org.

^# Contributed equally.

PMID: 33893398
PMCID: PMC8063779
DOI: 10.1038/s41422-021-00496-8

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

Haolin Liu et al. Cell Res. 2021 Jun.

. 2021 Jun;31(6):720-722.

doi: 10.1038/s41422-021-00496-8. Epub 2021 Apr 23.

Authors

Affiliations

¹ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA. Liuh@NJhealth.org.
² Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA. Liuh@NJhealth.org.
³ State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agriculture University, Beijing, 100193, China.
⁴ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA.
⁵ Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA.
⁶ Department of Medicine, National Jewish Health, Denver, CO, 80206, USA.
⁷ Department of Nursing, National Jewish Health, Denver, CO, 80206, USA.
⁸ Chinese Academy of Medical Sciences, Department of Biochemistry and Molecular Biology, Peking Union Medical College, Tsinghua University, Beijing, 100005, China.
⁹ Department of Biochemistry, Emory University of School of Medicine, Atlanta, GA, 30322, USA.
¹⁰ Department of Pharmacy, National Jewish Health, Denver, CO, 80206, USA.
¹¹ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA. Marrackp@NJhealth.org.
¹² Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA. Marrackp@NJhealth.org.
¹³ Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, 80206, USA. Zhangg@NJhealth.org.
¹⁴ Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, 80216, USA. Zhangg@NJhealth.org.

^# Contributed equally.

PMID: 33893398
PMCID: PMC8063779
DOI: 10.1038/s41422-021-00496-8

No abstract available

PubMed Disclaimer

Conflict of interest statement

H.L. is partially supported by NB Life Laboratory LLC and G.Z. holds equity at NB Life Laboratory LLC.

Figures

**Fig. 1. The UK variant Y501-RBD binds to ACE2 with higher affinity, but remains similar bindings to Bamlanivimab and sera from mRNA-vaccinated individuals.**
a The affinity measurement of N501-RBD to ACE2 by SPR. K_D, dissociation constant; K_on, association rate; K_off, dissociation rate; RU, response unit. b The affinity measurement of Y501-RBD to ACE2 by SPR. c Protein structure of N501-RBD and ACE2. d Protein structure model of Y501-RBD and ACE2. The new hydrogen bonds are shown as heavy dash lines, and the aromatic stacking interaction is shown as light dash lines. e Blocking of ACE2 binding to N501-RBD by different dilutions of mRNA-vaccinated serum. f Blocking of ACE2 binding to Y501-RBD by different dilutions of mRNA-vaccinated serum. Note that equal amount of N501-RBD and Y501-RBD was coated on two separate channels on the same CM5 chip. Same amount of serum as well as ACE2 were applied in the following dilution steps. Similar amounts of antibodies were retained on both channels (Supplementary information, Fig. S3). g. The difference of ACE2 retained on N501-RBD and Y501-RBD treated with serial dilutions of the serum at 5 s after ACE2 injection. Each dot value was calculated as the ACE2 binding on Y501-RBD minus ACE2 on N501-RBD. The value of Buffer is the difference of ACE2 on two channels without treatment of the serum. h The affinity measurement of N501-RBD to Bamlanivimab by SPR. i The affinity measurement of Y501-RBD to Bamlanivimab by SPR.

See this image and copyright information in PMC

Update of

The basis of a more contagious 501Y.V1 variant of SARS-COV-2.
Liu H, Zhang Q, Wei P, Chen Z, Aviszus K, Yang J, Downing W, Peterson S, Jiang C, Liang B, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G. Liu H, et al. bioRxiv [Preprint]. 2021 Feb 2:2021.02.02.428884. doi: 10.1101/2021.02.02.428884. bioRxiv. 2021. Update in: Cell Res. 2021 Jun;31(6):720-722. doi: 10.1038/s41422-021-00496-8 PMID: 33564771 Free PMC article. Updated. Preprint.

Cited by

Large-Vessel Occlusion Stroke Treated by Endovascular Thrombectomy in Patient with Coronavirus Disease 2019.
Tsurumi Y, Matsubara N, Yokoyama H, Hososhima O, Tsurumi A. Tsurumi Y, et al. Asian J Neurosurg. 2022 Sep 7;17(3):489-494. doi: 10.1055/s-0042-1750807. eCollection 2022 Sep. Asian J Neurosurg. 2022. PMID: 36398183 Free PMC article.
Neutralizing monoclonal antibodies for treatment of COVID-19.
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Taylor PC, et al. Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19. Nat Rev Immunol. 2021. PMID: 33875867 Free PMC article. Review.
Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.
Huang J, Ma Q, Su Z, Cheng X. Huang J, et al. Int J Mol Sci. 2024 Oct 9;25(19):10820. doi: 10.3390/ijms251910820. Int J Mol Sci. 2024. PMID: 39409149 Free PMC article. Review.
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera.
Vidal SJ, Collier AY, Yu J, McMahan K, Tostanoski LH, Ventura JD, Aid M, Peter L, Jacob-Dolan C, Anioke T, Chang A, Wan H, Aguayo R, Ngo D, Gerszten RE, Seaman MS, Barouch DH. Vidal SJ, et al. J Virol. 2021 Jun 24;95(14):e0040421. doi: 10.1128/JVI.00404-21. Epub 2021 Jun 24. J Virol. 2021. PMID: 33893169 Free PMC article.
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.
Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W, Peterson S, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G. Liu H, et al. MAbs. 2021 Jan-Dec;13(1):1919285. doi: 10.1080/19420862.2021.1919285. MAbs. 2021. PMID: 34074219 Free PMC article.

See all "Cited by" articles

References

1. U. S. Food & Drug. Pfizer-BioNTech vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).
1. U. S. Food & Drug. Moderna vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).
1. CDC. SARS-CoV-2 variants. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scie... (2021).
1. U. S. Food & Drug. Bamlanivimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).
1. U. S. Food & Drug. Casirivimab & imdevimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] U. S. Food & Drug. Pfizer-BioNTech vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).

[2] U. S. Food & Drug. Pfizer-BioNTech vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).

[3] U. S. Food & Drug. Moderna vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).

[4] U. S. Food & Drug. Moderna vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).

[5] CDC. SARS-CoV-2 variants. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scie... (2021).

[6] CDC. SARS-CoV-2 variants. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scie... (2021).

[7] U. S. Food & Drug. Bamlanivimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).

[8] U. S. Food & Drug. Bamlanivimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).

[9] U. S. Food & Drug. Casirivimab & imdevimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).

[10] U. S. Food & Drug. Casirivimab & imdevimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

Affiliations

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

Authors

Affiliations

Conflict of interest statement

Figures

Update of

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Conflict of interest statement

Figures

Update of

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous